Abstract:Holly A Maulhardt, 1 Alyson M Marin, 1 Gere S diZerega 1, 2 1 US Biotest, Inc, San Luis Obispo, CA, USA; 2 Nanology, LLC, Fort Worth, TX, USA Correspondence: Gere S diZerega, US Biotest, Inc, 231 Bonetti Drive, Suite 240, San Luis Obispo, CA, 93401, USA, Tel +01 805 595 1300, Email The effects of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) alone and in combination with systemic administration of the programmed cell death protein antibody (anti-mPD-1) were evaluated in a syngeneic murine model of melanoma. Groups of mice with subcutaneously implanted Clone M3 (Cloudman S91) tumors were treated with single and combination therapies. Tumor volume (TV) measurements, body weights, and clinical observations were followed in-life. At end of study, tumor-site tissues were collected, measured, and processed for flow cytometry along with blood and lymph nodes. The combination of LSAM-PTX + anti-mPD-1 resulted in an antitumoral response, which produced a significant decrease in TV compared to control animals. TV decreases also occurred in the LSAM-PTX and anti-mPD-1 groups. Flow cytometry analysis found increases in granulocytes and M2 macrophages and decreases in dendritic cells (DC) and monocytic myeloid-derived suppressor cells (M-MDSC) in tumor-site tissues. Increases in granulocytes and decreases in CD4+ T cells, macrophages, and M1 macrophages were found in the blood of animals administered the combination treatment. Increases in natural killer (NK) cells were found in lymph node tissue in the combination treatment group. These findings suggest that IT LSAM-PTX may provide benefit in the local treatment of melanomas and may synergize with systemic anti-PD-1 therapy, leading to additional tumoricidal outcomes without added systemic toxicity. Keywords: clone M-3, nanopac, combinatorial immunotherapy, PD-1 Combinations of immune checkpoint blockade with chemotherapy, targeted, oncolytic, or anti-angiogenic treatments have shown encouraging results. 1–4 Transdermal drug delivery systems, such as liposomes, micelles, hydrogels, and emulsions, can facilitate skin permeation and deposition resulting in continuous tumor cell drug exposure. 3,5,6 The approval of talimogene laherparepvec, an attenuated herpesvirus expressing human granulocyte-macrophage colony-stimulating factor (huGM-CSF), for the intralesional treatment of cutaneous, subcutaneous, and nodal lesions established intratumoral (IT) therapy for melanoma treatment. 7 Previously, we reported that IT administration of large surface area microparticle docetaxel (LSAM-DTX) reduced primary and metastatic orthotopic breast cancer in a syngeneic mouse model and anti-tumor activity was further enhanced by addition of systemic treatment with the cytotoxic T lymphocyte antigen 4 antibody (anti-mCTLA-4). 8 This report describes the synergistic reduction in a murine melanoma tumor model (Clone M-3 (Cloudman S91)) following IT administration of a large surface area microparticle paclitaxel (LSAM-PTX) in combination with systemic administration of the programmed cell death protein 1 antibody (anti-mPD-1). LSAM-DTX and LSAM-PTX are investigational products not yet approved for use by the US Food and Drug Administration. The long residence time of LSAM-PTX within the tumor acts as a drug depot, resulting in continuous release of paclitaxel, exposing tumor cells to high, therapeutic levels of chemotherapeutic for several weeks. 9 In addition to the tumoricidal effects of local LSAM-PTX and LSAM-DTX therapy, immunomodulation, including increases in the concentration of innate and adaptive immune cells in the tumor and peripheral blood have also been reported in early-phase clinical studies. 9–12 Immune modulation has also been found in preclinical investigations including increases in immune effector cells in the peripheral blood following LSAM-DTX injections into mouse models of renal (Renca tumors) 13 and breast cancer (4T-1 tumors). 8 In this study, local LSAM-PTX alone and in combination with systemic anti-mPD-1 was evaluated for efficacy and immunomodulation in a syngeneic murine orthotopic melanoma model. Female DBA/2N mice (DBA/2NCrl, Charles River GmbH, Sulzfeld, Germany) were 5 to 10 weeks old on study Day 0. Animals were fed ad libitum water and V1126-000 Complete Feed (ssniff Spezialdiäten GmbH, Soest, Germany) and housed maximum 4/ventilated cage on a 12-h light cycle at 22 ± 2°C/45–65% humidity. Daily monitoring for clinical signs and abnormalities and three-time weekly weighing occurred for the duration of the study. Deviations of the health status of the animals were documented, and animals were euthanized individually before study termination when ethical abortion criteria were reached -Abstract Truncated-

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model

Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model

Active Specific Immunotherapy in Patients with Melanoma

Abstract 6344: Engineering of ICAM-1 refractory antibodies for the development of therapeutic antibodies and antibody drug conjugates (ADCs) in ICAM-1 over-expressing cancers

Intratumoral immunocytokine treatment results in enhanced antitumor effects

Abstract 1754: Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models

Abstract 3242: Efficacy evaluation by novel humanized mouse models for preclinical study of ADCs combined with immunotherapy

Abstract 2836: Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolvTM hIL-15 NOG mouse model

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1

Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

Cyclophosphamide augments the efficacy of in situ vaccination in a mouse melanoma model

Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model

Abstract 2713: Novel anti-PD-L1-IL-15 diabody immunocytokine in combination with radiation therapy improves response rates in immune-resistant murine head and neck cancer

Abstract B024: First-in-class Antibody Targeting Soluble NKG2D Ligand Smic to Enhance Checkpoint Cancer Immunotherapy

Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Abstract 2902: CA-4948 (emavusertib) improves treatment response of preclinical metastatic brain melanoma to anti-PD-1 immune checkpoint blockade

Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition

Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma